No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Times cited: 2
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
Times cited: 6